STAGE IV NON-SMALL CELL LUNG CANCER

This phase 2 trial tests the drug crizotinib (XALKORI) in people with advanced non-small cell lung cancer that has spread and carries a change in the ROS1 or MET gene. Participants take crizotinib by mouth twice daily. The study aims to see how well the drug shrinks tumors and de…

This study tested whether adding cetuximab (an antibody) to afatinib (a targeted pill) helps people with advanced EGFR-mutant lung cancer live longer. 174 patients were randomly assigned to receive either the combination or afatinib alone. The results showed no significant improv…

This early-phase study tested a new drug called ONO-7475 combined with the standard targeted therapy osimertinib in 78 people with advanced EGFR-mutated non-small cell lung cancer. The goal was to see if the combination is safe and tolerable. Participants had stage IIIB, IIIC, IV…

This early study tested combining the immunotherapy drug pembrolizumab with precise radiation (stereotactic radiosurgery) in 25 people with melanoma or lung cancer that had spread to the brain. The main goal was to check for serious side effects. Researchers also tracked how long…

This study tested a combination of a cancer vaccine (TG4010) and an immunotherapy drug (nivolumab) in 13 people with advanced non-small cell lung cancer who had already received other treatments. The goal was to see if the combination could shrink tumors or stop them from growing…

This study tested whether adding high-dose, precisely targeted radiation to standard immunotherapy can improve outcomes for people with stage IV non-small cell lung cancer. Forty-five adults who were already on immunotherapy received radiation to some of their tumors. Researchers…

This study tested a combination of two drugs—sEphB4-HSA and pembrolizumab—in 42 people with advanced non-small cell lung cancer or head & neck cancer that had spread or returned. The goal was to see if the combo could shrink tumors better than standard treatments. Participants ha…

This study tested two drugs—auranofin (originally for arthritis) and sirolimus (an immune suppressant)—in 29 people with advanced or recurrent lung cancer who had no standard options left. The goal was to find the safest dose and see if the combination could slow cancer growth. T…

This early-phase trial tested a precise, high-dose radiation technique called stereotactic body radiotherapy (SBRT) in 42 patients with breast, lung, or prostate cancer that had spread to several places in the body. The main goal was to find the safest dose and check for side eff…